KPTI
Karyopharm Therapeutics Inc. NASDAQ Listed Nov 6, 2013$9.02
-4.04%
vs $9.40
Mkt Cap $98.6M
52w Low $3.77
83.1% of range
52w High $10.09
50d MA $8.76
200d MA $7.28
P/E (TTM)
-0.5x
EV/EBITDA
—
P/B
—
Debt/Equity
-0.8x
ROE
66.9%
P/FCF
-1.3x
RSI (14)
49.20
ATR (14)
$0.73
Beta
0.40
50d MA
$8.76
200d MA
$7.28
Avg Volume
436.2K
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
85 Wells Avenue · Newton, MA 02459 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 14, 2026 | BMO | -1.45 | -1.02 | +29.7% | 8.85 | +7.7% | +0.6% | -13.8% | -6.9% | +4.6% | +6.8% | — |
| Feb 12, 2026 | BMO | -2.26 | -2.23 | +1.3% | 8.94 | +0.4% | -4.0% | +9.6% | -1.6% | +4.5% | +0.0% | — |
| Nov 3, 2025 | BMO | -3.47 | -3.82 | -10.1% | 6.07 | -1.2% | -6.9% | -5.1% | -2.6% | -1.1% | +5.4% | — |
| Aug 11, 2025 | BMO | -3.80 | -4.32 | -13.7% | 3.77 | -0.8% | +6.6% | +10.7% | +4.5% | +27.3% | -5.6% | — |
| May 12, 2025 | BMO | -4.21 | -2.77 | +34.2% | 6.15 | -6.5% | -20.0% | -1.4% | +12.2% | -2.2% | -3.6% | — |
| Feb 19, 2025 | BMO | -3.90 | -3.60 | +7.7% | 9.00 | +1.9% | +1.7% | -1.9% | -0.6% | -4.3% | +15.0% | — |
| Nov 5, 2024 | BMO | -4.05 | -3.90 | +3.7% | 12.69 | +0.5% | +4.8% | -0.5% | -0.6% | +5.2% | -2.6% | — |
| Aug 6, 2024 | BMO | -4.35 | -3.00 | +31.0% | 12.60 | +1.2% | -3.4% | +3.4% | -3.4% | +0.6% | +2.2% | — |
| May 8, 2024 | BMO | -4.95 | -4.80 | +3.0% | 15.30 | +2.0% | +4.9% | +1.9% | +2.8% | -2.7% | +3.7% | — |
| Feb 29, 2024 | BMO | -4.35 | -5.40 | -24.1% | 17.40 | +2.6% | +2.1% | +10.6% | -4.9% | +6.8% | +15.0% | — |
| Nov 2, 2023 | BMO | -4.20 | -4.50 | -7.1% | 11.42 | +1.7% | +16.9% | -1.1% | -9.2% | -6.2% | -7.6% | — |
| Aug 2, 2023 | BMO | -5.10 | -4.35 | +14.7% | 26.85 | +0.6% | +1.1% | -5.0% | -6.4% | +2.5% | -1.8% | — |
| May 4, 2023 | AMC | -5.10 | -4.50 | +11.8% | 41.55 | +2.5% | -2.2% | -7.7% | -0.4% | +8.4% | -1.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 27 | Piper Sandler | Maintains | Overweight → Overweight | — | $8.66 | $8.99 | +3.8% | +0.0% | -0.7% | -2.3% | -1.1% | +5.5% |
| Mar 30 | Piper Sandler | Maintains | Overweight → Overweight | — | $5.48 | $5.40 | -1.5% | -3.3% | +5.1% | +4.5% | +1.2% | +7.3% |
| Mar 25 | Baird | Maintains | Outperform → Outperform | — | $5.44 | $5.36 | -1.5% | -4.2% | +6.9% | -1.6% | -3.3% | +5.1% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.44 | $5.36 | -1.5% | -4.2% | +6.9% | -1.6% | -3.3% | +5.1% |
| Feb 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.40 | $9.64 | +2.6% | -1.6% | +4.5% | +0.0% | +3.7% | +0.4% |
| Nov 4 | RBC Capital | Maintains | Outperform → Outperform | — | $6.07 | $6.00 | -1.2% | -6.9% | -5.1% | -2.6% | -1.1% | +5.4% |
| Oct 13 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $5.50 | $6.01 | +9.3% | +2.2% | +2.7% | +3.1% | +1.3% | -1.7% |
| Oct 9 | Baird | Maintains | Outperform → Outperform | — | $5.90 | $5.61 | -4.9% | -1.4% | -5.5% | +2.2% | +2.7% | +3.1% |
| Oct 9 | Piper Sandler | Maintains | Overweight → Overweight | — | $5.90 | $5.61 | -4.9% | -1.4% | -5.5% | +2.2% | +2.7% | +3.1% |
| Aug 12 | Baird | Maintains | Outperform → Outperform | — | $3.77 | $3.74 | -0.8% | +6.6% | +10.7% | +4.5% | +27.3% | -5.6% |
| Jul 16 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $4.24 | $4.22 | -0.5% | -1.4% | -2.6% | -5.4% | +4.4% | -3.2% |
| May 13 | Baird | Maintains | Outperform → Outperform | — | $6.15 | $5.75 | -6.5% | -20.0% | -1.4% | +12.2% | -2.2% | -3.6% |
| May 13 | Barclays | Maintains | Overweight → Overweight | — | $6.15 | $5.75 | -6.5% | -20.0% | -1.4% | +12.2% | -2.2% | -3.6% |
| May 13 | RBC Capital | Maintains | Outperform → Outperform | — | $6.15 | $5.75 | -6.5% | -20.0% | -1.4% | +12.2% | -2.2% | -3.6% |
| Mar 3 | Baird | Maintains | Outperform → Outperform | — | $7.95 | $7.83 | -1.5% | -8.8% | -12.1% | -3.9% | +1.6% | +10.8% |
| Feb 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.55 | $8.78 | +2.7% | +15.0% | -15.1% | -4.8% | -8.8% | -12.1% |
| Feb 20 | RBC Capital | Maintains | Outperform → Outperform | — | $9.00 | $9.17 | +1.9% | +1.7% | -1.9% | -0.6% | -4.3% | +15.0% |
| Feb 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.00 | $9.17 | +1.9% | +1.7% | -1.9% | -0.6% | -4.3% | +15.0% |
| Feb 10 | RBC Capital | Maintains | Outperform → Outperform | — | $9.47 | $9.75 | +3.0% | -1.4% | -4.0% | -2.0% | +4.1% | +1.1% |
| Jan 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.50 | $10.05 | +5.8% | +0.4% | +9.7% | -5.4% | +4.0% | -2.9% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.69 | $12.75 | +0.5% | +4.8% | -0.5% | -0.6% | +5.2% | -2.6% |
| Nov 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $12.69 | $12.75 | +0.5% | +4.8% | -0.5% | -0.6% | +5.2% | -2.6% |
| Nov 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.85 | $14.85 | +0.0% | -8.8% | +3.3% | -9.4% | +4.8% | -0.5% |
| Aug 7 | Baird | Maintains | Outperform → Outperform | — | $12.60 | $12.75 | +1.2% | -3.4% | +3.4% | -3.4% | +0.6% | +2.2% |
| Aug 7 | RBC Capital | Maintains | Outperform → Outperform | — | $12.60 | $12.75 | +1.2% | -3.4% | +3.4% | -3.4% | +0.6% | +2.2% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.60 | $12.75 | +1.2% | -3.4% | +3.4% | -3.4% | +0.6% | +2.2% |
| Jun 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.60 | $14.29 | -2.1% | -10.9% | -6.0% | -1.9% | +3.5% | -1.1% |
| Jun 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.54 | $14.70 | +1.1% | +1.9% | -6.1% | +7.3% | -2.2% | -1.3% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.30 | $15.60 | +2.0% | +4.9% | +1.9% | +2.8% | -2.7% | +3.7% |
| Mar 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.40 | $17.85 | +2.6% | +2.1% | +10.6% | -4.9% | +6.8% | +15.0% |
| Nov 3 | RBC Capital | Maintains | Outperform → Outperform | — | $11.42 | $11.61 | +1.7% | +16.9% | -1.1% | -9.2% | -6.2% | -7.6% |
| Nov 3 | Piper Sandler | Maintains | Overweight → Overweight | — | $11.42 | $11.61 | +1.7% | +16.9% | -1.1% | -9.2% | -6.2% | -7.6% |
| Aug 7 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $25.80 | $25.80 | +0.0% | -6.4% | +2.5% | -1.8% | +3.1% | +1.8% |
| Aug 3 | Piper Sandler | Maintains | Overweight → Overweight | — | $26.85 | $27.00 | +0.6% | +1.1% | -5.0% | -6.4% | +2.5% | -1.8% |
| Aug 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.85 | $27.00 | +0.6% | +1.1% | -5.0% | -6.4% | +2.5% | -1.8% |
| Aug 3 | RBC Capital | Maintains | Outperform → Outperform | — | $26.85 | $27.00 | +0.6% | +1.1% | -5.0% | -6.4% | +2.5% | -1.8% |
| Jul 26 | Wedbush | Maintains | Neutral → Neutral | — | $23.85 | $23.25 | -2.5% | +8.8% | -2.3% | +6.5% | +0.0% | +0.0% |
| Jul 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.85 | $23.25 | -2.5% | +8.8% | -2.3% | +6.5% | +0.0% | +0.0% |
| Jul 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.95 | $27.30 | +19.0% | -2.6% | +7.4% | +0.6% | +3.1% | -1.8% |
| May 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $41.55 | $42.60 | +2.5% | -2.2% | -7.7% | -0.4% | +8.4% | -1.9% |
| May 5 | Baird | Maintains | Outperform → Outperform | — | $41.55 | $42.60 | +2.5% | -2.2% | -7.7% | -0.4% | +8.4% | -1.9% |
| May 5 | RBC Capital | Maintains | Outperform → Outperform | — | $41.55 | $42.60 | +2.5% | -2.2% | -7.7% | -0.4% | +8.4% | -1.9% |
| Apr 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $62.25 | $62.70 | +0.7% | -0.2% | -8.2% | +7.6% | +0.0% | -8.3% |
| Feb 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $48.00 | $48.30 | +0.6% | -0.6% | +0.0% | -5.7% | +1.3% | -0.7% |
| Feb 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $54.90 | $54.75 | -0.3% | -1.9% | -1.1% | -9.9% | -0.6% | +0.0% |
| Jan 27 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $46.95 | $47.55 | +1.3% | +1.6% | -3.1% | +7.1% | +1.2% | +5.1% |
| Jan 19 | Piper Sandler | Maintains | Overweight → Overweight | — | $46.05 | $48.30 | +4.9% | +8.8% | +0.9% | -3.6% | +2.2% | -3.0% |
| Jan 10 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $42.60 | $42.45 | -0.4% | +1.1% | +3.1% | +3.0% | +8.2% | -5.8% |
| Jan 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $42.60 | $42.45 | -0.4% | +1.1% | +3.1% | +3.0% | +8.2% | -5.8% |
| Nov 4 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $68.10 | $75.75 | +11.2% | +4.4% | +8.6% | +3.9% | +1.1% | +6.1% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 14, 2026 | Cheng Sohanya Roshan | EVP & Chief Commercial Officer | Sell | 324 | $9.50 | $3K | 107,940 | -6.91% | +1.24% |
| May 14, 2026 | Paulson Richard A. | President and CEO | Sell | 2,203 | $9.50 | $21K | 269,747 | -6.91% | +1.24% |
| May 14, 2026 | Abate Kristin | Chief Accounting Officer | Sell | 53 | $9.50 | $504 | 23,801 | -6.91% | +1.24% |
| May 14, 2026 | Rangwala Reshma | EVP & Chief Medical Officer | Sell | 408 | $9.50 | $4K | 56,829 | -6.91% | +1.24% |
| May 14, 2026 | Poulton Stuart | EVP, Chief Development Officer | Sell | 403 | $9.50 | $4K | 94,821 | -6.91% | +1.24% |
| May 14, 2026 | Mano Michael | EVP, CLO&Secretary | Sell | 266 | $9.50 | $3K | 94,398 | -6.91% | +1.24% |
8-K · 5.02
!!! Very High
Karyopharm Therapeutics Inc. -- 8-K 5.02: Executive Change
Karyopharm Therapeutics appointed Reshma Rangwala as a new director, expanding its board composition and potentially strengthening governance oversight of the nuclear export inhibitor company.
May 28
8-K · 2.02
!! High
Karyopharm Therapeutics Inc. -- 8-K 2.02: Earnings Results
Karyopharm Therapeutics announced Q1 2026 earnings results and will hold a conference call to discuss financial performance and business updates.
May 14
8-K
Unknown — 8-K Filing
Karyopharm's runway extending to Q3 2026 suggests manageable near-term solvency, but investors should monitor burn rate closely as the company relies on product revenue growth to avoid future dilutive financing.
Mar 27
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Equity Issuance
KPTI's equity issuance agreement with RA Capital likely dilutes existing shareholders but provides needed capital for operations or clinical development, a mixed signal for near-term stock performance.
Mar 24
8-K · 5.02
!!! Very High
Zevra Therapeutics, Inc. -- 8-K 5.02: Executive Change
Zevra Therapeutics appointed Justin Renz as Chief Financial Officer while he resigned from the board, effective March 9, 2026, signaling potential leadership restructuring.
Mar 9
8-K · 8.01
!! High
Karyopharm Therapeutics Inc. -- 8-K 8.01: Material Event / Announcement
Karyopharm Therapeutics secured a forbearance agreement delaying debt obligations until late 2026, contingent on completing a capital raise to improve liquidity and avoid default.
Mar 3
8-K
Karyopharm Therapeutics Inc. -- 8-K Filing
I cannot provide a meaningful investor analysis from this filing, as the summary contains only technical XBRL metadata and reference information rather than substantive business details or corporate actions.
Feb 19
8-K
Karyopharm Therapeutics Inc. -- 8-K Filing
Karyopharm Therapeutics reported $115 million in 2025 XPOVIO revenue and guided 2026 total revenue to $130-$150 million, indicating modest growth expectations for its lead oncology drug.
Feb 12
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Opaleye Management Inc. | 930,000 | $7M | New | Dec 2025 |
| 2 | Vanguard Capital Management Llc | 739,745 | $4M | New | Mar 2026 |
| 3 | Avidity Partners Management Lp | 463,741 | $3M | New | Mar 2026 |
| 4 | Soleus Capital Management, L.p. | 440,000 | $2M | — | Mar 2026 |
| 5 | Millennium Management | 420,571 | $2M | New | Mar 2026 |
| 6 | Braidwell Lp | 303,370 | $2M | New | Dec 2025 |
| 7 | Davidson Kempner Capital Management Lp | 300,000 | $2M | New | Mar 2026 |
| 8 | Acadian Asset Management Llc | 248,957 | $1M | Added | Mar 2026 |
| 9 | Ubs Group Ag | 194,017 | $1M | Added | Mar 2026 |
| 10 | Two Sigma Investments, Lp | 151,232 | $842K | Added | Mar 2026 |
| 11 | Adar1 Capital Management, Llc | 136,736 | $762K | New | Mar 2026 |
| 12 | Silverback Asset Management Llc | 130,000 | $724K | Added | Mar 2026 |
| 13 | Marshall Wace, Llp | 128,451 | $715K | — | Mar 2026 |
| 14 | Renaissance Technologies Llc | 105,414 | $587K | Added | Mar 2026 |
| 15 | Connor, Clark & Lunn Investment Management Ltd. | 57,212 | $421K | New | Dec 2025 |
| 16 | Royal Bank Of Canada | 60,399 | $336K | Added | Mar 2026 |
| 17 | Jane Street Group, Llc | 35,533 | $262K | New | Dec 2025 |
| 18 | Northern Trust Corp | 38,556 | $215K | Added | Mar 2026 |
| 19 | Centiva Capital, Lp | 30,210 | $168K | New | Mar 2026 |
| 20 | Baird Financial Group, Inc. | 29,791 | $166K | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 9
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 90,084 | $848K | Feb 2026 |
| 2 | Fidelity Total Market Index Fund | 30,230 | $284K | Feb 2026 |
| 3 | Ultra-Small Company Fund | 49,873 | $278K | Mar 2026 |
| 4 | iShares Micro-Cap ETF | 42,667 | $238K | Mar 2026 |
| 5 | Fidelity Series Total Market Index Fund | 23,866 | $225K | Feb 2026 |
| 6 | Ultra-Small Company Market Fund | 22,000 | $123K | Mar 2026 |
| 7 | Fidelity Nasdaq Composite Index Fund | 10,033 | $94K | Feb 2026 |
| 8 | Schwab Total Stock Market Index Fund | 3,400 | $22K | Jan 2026 |
| 9 | Knights of Columbus U.S. ALL CAP INDEX FUND | 77 | $500 | Jan 2026 |
Valuation
Market Cap
$98.6M
Enterprise Value
$240.8M
P/E (TTM)
-0.50x
Forward P/E
—
PEG Ratio
-0.00x
P/B
—
P/S
0.68x
P/FCF
-1.31x
EV/EBITDA
—
Shares Out
10.9M
Financials (TTM)
Revenue
$146.1M
Net Income
-$196.0M
EBITDA
-$90.4M
Free Cash Flow
-$75.4M
Op Cash Flow
-$75.4M
EPS Basic
$-17.93
EPS Diluted
$-17.93
EPS Forward
$-4.37
Gross Margin
95.9%
Op Margin
-62.1%
Net Margin
-134.2%
Balance Sheet
Total Assets
$108.4M
Total Liab.
$401.3M
Total Equity
-$292.9M
Cash
$63.7M
LT Debt
$205.9M
Book Value/Sh
$-26.79
Debt/Equity
-0.80x
Current Ratio
1.12
Quick Ratio
1.08
Returns & Growth
ROE
66.9%
ROA
-180.8%
ROIC
-236.6%
Rev Growth YoY
+0.6%
EPS Growth YoY
-90.5%
Price Returns
2W
+2.2%
1M
+9.5%
3M
-3.3%
6M
+61.9%
12M
+116.7%
Technicals
52W High
$10.09
52W Low
$3.77
50d MA
$8.76
200d MA
$7.28
RSI (14)
49.20
ATR (14)
$0.73
Beta
0.40
Avg Volume
436K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$18.75
High
$28.00
Low
$12.00
Median
$17.50
Data updated apr 25, 2026 5:55pm
· Source: financialmodelingprep.com